10-Q quarterly report · filed Nov 9, 2026

Tango Therapeutics, Inc. (TNGX) Q3 2026 10-Q Quarterly Report

Short answer

Tango Therapeutics, Inc. (TNGX) filed its Q3 2026 10-Q quarterly report on Nov 9, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $0 (down 100.0% year over year) with net income of −$68M.

Q3 2026 key financials · XBRL

Revenue
$0
−100.0% YoY
Net income
−$68M
−530.6% YoY · −23.6% QoQ
EPS (diluted)
−$0.40
−385.7% YoY · −11.1% QoQ

Source: XBRL data from the Tango Therapeutics, Inc. (TNGX) Q3 2026 10-Q on SEC EDGAR. USD.

Tango Therapeutics, Inc. Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Quarterly collaboration revenue $0, down $53.8M YoY from Gilead recognition
  • Net loss $68.4M vs net income $15.9M YoY; operating margin not disclosed
  • Vopimetostat plus daraxonrasib: 82% ORR and 88% nine-month PFS in 22 PDAC patients
  • Cash, equivalents and marketable securities $977.5M; operating cash use $120.4M through nine months
  • Outlook: $977.5M funds operations at least twelve months; registrational trial expected first half 2027

Risk Factors

  • New combination-supply risk: daraxonrasib supply uncertainty threatens planned global registrational trial in first half of 2027
  • Regulatory risk: third-party combination drugs may lack regulatory approval or remain unavailable for clinical and commercial use
  • Operational risk: failure to secure daraxonrasib could delay development timelines
  • Financial risk: purchasing checkpoint inhibitors or comparator therapies may increase development costs
  • Partnership risk: loss of collaborations with Revolution Medicines, Lilly, or Erasca could disrupt combination trials

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other Tango Therapeutics, Inc. quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.